NCT01681264: Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance |
|
|
| Active, not recruiting | 4 | 200 | US | Morphine, MS Contin, Guanfacine 1mg, Intuniv, Tenex, Guanfacine 2mg, Placebo, Sugar Pill | Massachusetts General Hospital, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Chronic Pain | 12/22 | 12/23 | | |
PWS-GXR, NCT05657860: Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome |
|
|
| Recruiting | 4 | 33 | US | Guanfacine Extended Release, Intuniv, Placebo | Maimonides Medical Center | Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking | 01/24 | 01/24 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
